颌骨骨坏死是最近报道的应用双膦酸盐类药物时出现的一种不良反应;对骨代谢周转的过度抑制是导致这种不良反应发生的主要机制。患有多发性骨髓瘤或肿瘤骨转移癌患者,接受胺基双膦酸盐类药物静脉给药,发生颌骨骨坏死的风险最大。 Osteonecrosis of the jaw is a recently reported adverse reaction to the use of bisphosphonates; excessive inhibition of turnover of the bone metabolism is the primary mechanism responsible for this adverse reaction. People with multiple myeloma or metastatic cancer of the tumor receiving intravenous administration of the aminobisphosphonate have the greatest risk of jaw osteonecrosis.